With the Trump administration's efforts to exert control over the Federal Reserve, most recently evidenced by the firing of Lisa Cook of the Fed's Board of Governors, the U.S. central bank is potentially entering a political environment that could have a dramatic impact on its public standing both inside and outside of the country. Analysts across Wall Street have sounded alarms about the potential repercussions of an erosion of public trust in the Fed. Those at Goldman Sachs and JPMorgan have speculated th ...

In August, the S&P 500 Index posted a moderate gain of around 2%, marking its fifth-best monthly performance of 2025. Although August wasn’t a standout month for the general market, it certainly was for three names. Below, we’ll detail the three stocks that led the month when it came to analysts boosting their price targets, all receiving more than 20 upgrades according to MarketBeat data. Get Shopify alerts:Updated Targets Continue to See Double-Digit Upside in SHOP First up is one of the most talked-about ...

Shares of Qualcomm Inc. NASDAQ: QCOM closed around $160 on Monday, once again running into resistance at a level they have struggled to clear since June. QUALCOMM TodayQCOMQUALCOMM$158.66 -1.58 (-0.99%) 52-Week Range$120.80▼$182.10Dividend Yield2.24%P/E Ratio15.30Price Target$182.82Add to WatchlistIt is the fourth time in as many months the stock has tested this level, and, compared to many of its peers, the chart is not a flattering one. And for many investors, Qualcomm has been a frustrating name to watc ...

Group 1: Biotechnology Investment Overview - Investing in biotechnology stocks is often seen as speculative due to many companies being in clinical or pre-clinical stages, typically not yet profitable and often pre-revenue [1] - Small-cap biotech stocks, particularly those trading under $5, may present opportunities for long-term returns for patient investors [2] Group 2: Hoth Therapeutics - Hoth Therapeutics (NASDAQ: HOTH) is currently priced at $1.46, down 35% from its 12-month high of $3.80, but has seen a 98% increase in 2025 [2][5] - The company has multiple pre-clinical assets, including an obesity drug candidate, and focuses on high-demand markets such as oncology and weight-loss treatments [3][5] - Hoth's pre-clinical oncology candidate, HT-KIT, has shown over 80% knockdown of KIT expression in laboratory settings, targeting aggressive cancers [4] - Analysts project a price target of $4 for Hoth, indicating a potential upside of 150% from current levels [5] Group 3: Silo Pharma - Silo Pharma (NASDAQ: SILO) is currently priced at $0.65, down 29% in 2025 but has gained over 7% in the last three months due to a joint venture with Hoth Therapeutics [7] - The partnership aims to develop Hoth's HT-VA obesity drug candidate, tapping into a market projected to exceed $100 billion globally [7] - Silo Pharma is also focused on developing novel formulations of traditional and psychedelic therapeutics, with four candidates in pre-clinical stages [8] - The company has launched a cryptocurrency treasury strategy, targeting investments in Bitcoin, Ethereum, and Solana [9] Group 4: Anixa Biosciences - Anixa Biosciences (NASDAQ: ANIX) is priced at $2.98 and is further along in its development, with two of its five drugs in Phase 1 clinical trials [10][11] - The company is developing its candidates through partnerships with notable institutions like the Moffitt Cancer Center and the Cleveland Clinic [12] - Analysts have set a consensus price target of $10 for Anixa, suggesting a potential upside of 197% [12]

Vertical Aerospace TodayEVTLVertical Aerospace$4.94 +0.38 (+8.33%) 52-Week Range$2.76▼$15.99Price Target$10.43Add to WatchlistFor innovative technology-driven companies, there comes a moment when the narrative must shift from dazzling prototypes to a credible blueprint for profitability. For Vertical Aerospace NYSE: EVTL, that moment is fast approaching. On Sept. 17, 2025, the company will host its Capital Markets Day in New York, an event where it is expected to provide a detailed update on its comprehens ...

Several mid-cap stocks have recently unveiled buyback programs that punch well above their weight. These companies aren’t just signaling confidence in their future—they’re committing serious capital to shareholders.  In fact, each of the four names below has authorized repurchases worth more than 5% of its total market value, creating meaningful support for their stocks and potential upside for investors. Get Post alerts:POST: Iconic U.S. Food Company Announces $500 Million Buyback Plan First up is one of t ...

Ulta Beauty TodayULTAUlta Beauty$509.29 -10.52 (-2.02%) 52-Week Range$309.01▼$539.00P/E Ratio19.53Price Target$543.13Add to WatchlistShakespeare once said that all that glisters may not be gold, but he clearly wasn’t talking about the impressive earnings numbers Ulta Beauty Inc. NASDAQ: ULTA has been reporting in 2025. The cosmetic kingpin posted another top and bottom-line beat in its Q2 2025 earnings report released after the Aug. 28 trading session, surpassing expectations in a number of different sales ...

Core Viewpoint - Figma's IPO was highly anticipated, with shares initially gaining nearly 158% on the first trading day, but have since declined approximately 55% as of September 8, raising questions about its investment potential following its first earnings report [3][4]. Company Overview - Figma operates in the digital design market, which is largely dominated by Adobe, a company valued among the top 10 software stocks globally [5]. - The company generated nearly $900 million in revenue over the last 12 months and has a self-estimated total addressable market of $33 billion, indicating less than 3% market penetration and significant growth potential [8]. Product Advantages - Figma's platform allows for real-time collaboration between creative and coding teams, offering a more efficient alternative to Adobe's solutions, which can be cumbersome for collaborative projects [7]. Financial Performance - In Q2, Figma's sales grew by 41%, slightly exceeding analyst expectations, but the stock fell nearly 20% due to a significant miss on earnings per share [9]. - The company reported a positive adjusted operating margin of 5% and an adjusted free cash flow margin of 24%, with expectations of 37% revenue growth for the full year [10]. Customer Metrics - Figma's net dollar retention rate among customers with annual recurring revenue of $10,000 or more was 129%, with customers spending 29% more than in the prior year's quarter, indicating strong product value [11]. Market Sentiment - Following Figma's Q2 report, Wall Street analysts lowered their price targets by an average of 15%, with a consensus price target of approximately $67.50, suggesting around 28% upside from the stock's closing price on September 8 [12]. - Figma's market cap was around $25.7 billion as of September 8, which is close to the $20 billion acquisition offer from Adobe in September 2022, with current quarterly revenues approximately 90% higher than at that time [13][14].

Every investor is preparing for the United States Federal Reserve to cut interest rates in September 2025, which will shift the fundamental makeup of the entire S&P 500. While the most popular names today may continue to rise, other logical ways exist to create additional upside in a specific group of companies that will benefit even more from lower interest rates. These companies have above-average leverage on their balance sheets, considering that the amounts paid on that debt will be much lower when inte ...

Interest rate cuts are often associated with accelerating most speculative behavior in the financial markets. The high likelihood of the Federal Reserve cutting rates this September 2025 is only amplifying those expectations further, which has many investors remaining hopeful that a stock like Strategy Inc. NASDAQ: MSTR will reach new 52-week highs. However, this might not be the case after all. Strategy TodayMSTRStrategy$329.58 -0.32 (-0.10%) 52-Week Range$121.30▼$543.00P/E Ratio29.16Price Target$552.50Ad ...